NASDAQ:KZIA Novogen Q4 2025 Earnings Report $9.60 -1.32 (-12.09%) Closing price 09/23/2026 04:00 PM EasternExtended Trading$9.90 +0.30 (+3.13%) As of 07:13 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Novogen EPS ResultsActual EPS-$6.14Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ANovogen Revenue ResultsActual Revenue$0.59 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ANovogen Announcement DetailsQuarterQ4 2025Date11/7/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Novogen Earnings HeadlinesNovogen Limited (NASDAQ:KZIA) Receives Average Recommendation of "Moderate Buy" from Brokerages4 hours ago | americanbankingnews.comKazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure DisordersSeptember 22 at 7:30 AM | prnewswire.comThey're shrinking your dollars every single monthSince 2020, the dollar has lost roughly a quarter of its buying power. A $500,000 nest egg today buys about what $375,000 did five years ago, even though no statement shows the change. Central banks have bought over 1,000 tonnes of gold a year for three straight years, using the same published data now explained in a free guide. The guide breaks down what's driving the shift in plain English, so readers can see the numbers for themselves.September 24 at 1:00 AM | American Alternative (Ad)Novogen Limited (NASDAQ:KZIA) Sees Significant Increase in Short InterestSeptember 19, 2026 | americanbankingnews.comKazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain CancerSeptember 9, 2026 | prnewswire.comKazia Therapeutics Limited (KZIA) Discusses Clinical and Corporate Updates With Focus on Paxalisib Programs in Breast and Colorectal Cancer TranscriptSeptember 4, 2026 | seekingalpha.comSee More Novogen Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Novogen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Novogen and other key companies, straight to your email. Email Address About NovogenNovogen (NASDAQ:KZIA), now known as Kazia Therapeutics Limited, is an Australia-based biotechnology company focused on developing therapies for cancer and other serious diseases. The company’s research has centered on targeted treatments designed to address tumors that are difficult to treat with conventional approaches. Kazia’s principal clinical program has been paxalisib, an orally administered inhibitor of the PI3K/mTOR pathway being investigated primarily for brain cancers, including glioblastoma. The company has also pursued other oncology candidates, including therapies intended to inhibit tumor growth and angiogenesis. Founded in Australia, Novogen developed its early drug-discovery and oncology programs before changing its name to Kazia Therapeutics in 2016. The company’s activities have included collaborations and clinical development programs involving research institutions and trial sites in Australia, the United States, and other international markets.View Novogen ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Energy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock?Thor Industries Is Boring—And That May Be Its Biggest AdvantageAutoZone Shifts Gears, On Track to Reverse Course and Price RecoveryMeta’s Muse Highlights Arm’s Growing Role in AI InfrastructureOld Dogs, New Tech: 3 Legacy Stocks Powering the AI Boom Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
